Fapon Connects Enzyme Innovation with Real-World Applications at AMP 2026
SEATTLE, Nov. 18, 2026
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.

![]()
Fapon Connects Enzyme Innovation with Real-World Applications at AMP 2026
PR Newswire
SEATTLE, Nov. 18, 2026
Fapon-hosted workshop highlights AI-powered enzyme engineering and application insights from full-length transcriptomics
SEATTLE, Nov. 18, 2026 /PRNewswire/ — Fapon, a globally leading life sciences organization, has concluded its participation in the Association for Molecular Pathology (AMP) 2026 Annual Meeting & Expo, held November 10–14 at the Seattle Convention Center. At Booth 1905, Fapon presented its latest advances in AI-engineered enzymes, application-specific reverse transcription solutions, and integrated RNA and DNA library preparation workflows, connecting innovations in enzyme development with the evolving needs of molecular diagnostics.
A key highlight of Fapon’s participation was its corporate workshop, “Unlocking the Full Potential of Enzymes in Molecular Diagnostics,” held on November 11. The session brought together perspectives on enzyme engineering and real-world applications, illustrating how advances in enzyme design can support performance across qPCR, RT-qPCR, NGS, and isothermal amplification.
Fapon’s Ning Wu, Ph.D., presented the company’s enzyme engineering platform, which combines AI-driven design with high-throughput wet-lab screening in an iterative process. Experimental results are fed back into the model to guide the selection of candidates for subsequent design rounds. After two rounds of design and selection, AI-engineered MMLV reverse transcriptases can generate cDNA from RNA templates up to 9 kb in length at 60°C. The session also discussed TeloScript II, a next-generation reverse transcriptase designed to extend full-length cDNA synthesis in long-read sequencing workflows, even for templates with complex secondary structures. An invited guest speaker shared application insights from a full-length transcriptomics study, demonstrating how long-read sequencing can help resolve complex fusion genes and transcript isoforms. The discussion also highlighted the role of reverse transcription performance in supporting demanding RNA sequencing workflows.
Advancing Enzyme Performance Across Molecular Diagnostic Workflows
Throughout the exhibition, Fapon showcased its enzyme portfolio developed through AI-driven design and experimental validation. Featured solutions included ProPrime II Taq DNA Polymerase, a second-generation antibody-based hot-start polymerase that is ultrafast and highly inhibitor-resistant. Its special antibody formulation enables complete antibody release within 10 seconds of heat activation. It enables 41 cycles of quadruplex qPCR to be completed in under 20 minutes. The enzyme has also been evaluated for direct amplification in 5% whole blood and in the presence of nine common PCR inhibitors. It is designed for multiplexed qPCR panels and near-patient testing, where speed and tolerance to challenging sample matrices are important for assay performance.
Another featured solution was MeloScript III WS Reverse Transcriptase, a third-generation warm-start RT specifically designed for one-step RT-qPCR. Like ProPrime II, it is highly inhibitor-resistant, and it maintains reverse transcription performance after 10 minutes at 52–64°C, supporting fast and specific one-step RT-qPCR. Its glycerol-free, lyophilization-ready format makes it suitable for lyophilized reagents and near-patient assay formats.
In addition to MeloScript III WS for RT-qPCR, Fapon also highlighted other application-specific reverse transcription solutions, including PreciAmp HS RT for RT-LAMP applications and VeloScript I for long-read sequencing and NGS workflows. PreciAmp HS RT maintains performance in the presence of inhibitors such as ethanol, viral preservation solutions, and sample release agents. VeloScript I synthesizes full-length cDNA up to 15 kb, even in the presence of complex secondary RNA structures, using RNA inputs ranging from 10 pg to 10 μg. Together with its RNA library preparation solutions, the portfolio supports a range of RNA applications, from reverse transcription to downstream sequencing.
Additional solutions on display included the NK081 Poly(A) mRNA Magnetic Isolation Module, which removes 95% or more of rRNA in under 40 minutes, and the NextGen Universal FS DNA Library Prep Kit, which completes library preparation in under one hour. These solutions broaden Fapon’s offerings across RNA and DNA sample preparation.
Connecting with the Molecular Diagnostics Community
During AMP 2026, Fapon’s team connected with molecular pathology researchers, assay developers, and IVD manufacturers to exchange perspectives on emerging application needs and technical challenges. These discussions provided opportunities to explore Fapon’s enzyme technologies, integrated workflow solutions, and potential areas for collaboration.
Fapon thanks everyone who visited its booth and participated in the workshop. The company looks forward to continuing conversations with the molecular diagnostics community and supporting partners with innovative enzyme technologies and workflow solutions.
To learn more about Fapon’s molecular diagnostics solutions, request product information or evaluation samples, or discuss potential collaboration opportunities, please contact:
Email: market_US@fapon.com
Website: https://us.faponbiotech.com/
About Fapon
Fapon, a globally leading life sciences organization, is redefining the R&D paradigm in diagnostics and therapeutics through a cutting-edge “AI-driven + a closed loop of dry and wet experiments” model. This approach significantly accelerates novel biomarker/target discovery and translation. We have established an integrated business structure that combines AI-powered innovative discovery, one-stop diagnostic solutions and novel therapies. Our products and services have covered the full spectrum of health management across the entire lifecycle, and accelerated the development of precision medicine. We have built a global network for R&D, manufacturing, marketing, sales and services, with products reaching over 70 countries and regions and more than 2,500 partners worldwide. Leveraging our AI-driven, diagnostics and therapeutics closed-loop innovation platforms, we connect healthcare resources across the globe, continuously contributing to a healthier and better future for all.
Follow us on LinkedIn (Fapon) or visit https://us.faponbiotech.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/fapon-connects-enzyme-innovation-with-real-world-applications-at-amp-2026-302943594.html
SOURCE Fapon



